drugset / Press release
LAPIX Therapeutics Announces First Patient Dosed in Phase Ib Study of LPX-TI641 in Atopic Dermatitis
2025-12-23 · LAPIX Therapeutics Inc. · original lapix.com ↗
• Study Evaluates New Oral Capsule Formulation in a Th2-Dominant Inflammatory Disease
The release as fetched from its publisher. lapix.com ↗